Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma.

Kinslow CJ, Rae AI, Neugut AI, Adams CM, Cheng SK, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Iwamoto FM, Sonabend AM, Wang TJC.

Br J Neurosurg. 2020 Jan 14:1-7. doi: 10.1080/02688697.2019.1710820. [Epub ahead of print]

PMID:
31931632
2.

Immunotherapy Against Gliomas: is the Breakthrough Near?

Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM.

Drugs. 2019 Nov;79(17):1839-1848. doi: 10.1007/s40265-019-01203-z. Review.

PMID:
31598900
3.

Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Jun;25(6):1022. doi: 10.1038/s41591-019-0449-8.

PMID:
30996326
4.

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R, Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J, Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto FM, Sonabend AM, Rabadan R.

Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11. Erratum in: Nat Med. 2019 Apr 17;:.

5.

In Reply: Craniotomy and Survival for Primary Central Nervous System Lymphoma.

Rae AI, Iwamoto FM, Sonabend AM.

Neurosurgery. 2018 Oct 1;83(4):E192. doi: 10.1093/neuros/nyy328. No abstract available.

PMID:
30085238
6.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

7.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

8.

Craniotomy and Survival for Primary Central Nervous System Lymphoma.

Rae AI, Mehta A, Cloney M, Kinslow CJ, Wang TJC, Bhagat G, Canoll PD, Zanazzi GJ, Sisti MB, Sheth SA, Connolly ES, McKhann GM, Bruce JN, Iwamoto FM, Sonabend AM.

Neurosurgery. 2019 Apr 1;84(4):935-944. doi: 10.1093/neuros/nyy096.

PMID:
29660011
9.

Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.

Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC.

J Neurooncol. 2018 Apr;137(2):303-311. doi: 10.1007/s11060-017-2718-z. Epub 2017 Dec 20.

PMID:
29264835
10.

Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis.

Yun J, Yang J, Cloney M, Mehta A, Singh S, Iwamoto FM, Neugut AI, Sonabend AM.

Front Neurol. 2017 Sep 12;8:478. doi: 10.3389/fneur.2017.00478. eCollection 2017.

11.

The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA.

Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029. Review.

12.

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA.

Blood. 2017 Jun 8;129(23):3071-3073. doi: 10.1182/blood-2017-01-764209. Epub 2017 Mar 29.

13.

Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection.

Yun J, Iwamoto FM, Sonabend AM.

Arch Cancer Res. 2016;4(2). pii: 71. doi: 10.21767/2254-6081.100071. Epub 2016 May 27.

14.

Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):306-314. doi: 10.1016/j.prro.2015.12.001. Epub 2015 Dec 4.

PMID:
26952813
15.

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

Odia Y, Sul J, Shih JH, Kreisl TN, Butman JA, Iwamoto FM, Fine HA.

CNS Oncol. 2016;5(2):59-67. doi: 10.2217/cns-2015-0010. Epub 2016 Feb 10.

16.

Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome.

Cloney M, D'Amico R, Lebovic J, Nazarian M, Zacharia BE, Sisti MB, Bruce JN, McKhann GM, Iwamoto FM, Sonabend AM.

World Neurosurg. 2016 May;89:362-7. doi: 10.1016/j.wneu.2015.12.096. Epub 2016 Jan 14.

PMID:
26775233
17.

A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas.

Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado CA, Li A, Kreisl TN, Sul J, Butman JA, Fine HA.

J Neurooncol. 2016 Mar;127(1):127-35. doi: 10.1007/s11060-015-2020-x. Epub 2015 Dec 7.

PMID:
26643807
18.

The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma.

D'Amico RS, Cloney MB, Sonabend AM, Zacharia B, Nazarian MN, Iwamoto FM, Sisti MB, Bruce JN, McKhann GM 2nd.

World Neurosurg. 2015 Oct;84(4):913-9. doi: 10.1016/j.wneu.2015.05.072. Epub 2015 Jun 11.

PMID:
26074434
19.

Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.

Iwamoto FM.

Neurology. 2015 Jan 20;84(3):285. doi: 10.1212/WNL.0000000000001170. Epub 2014 Dec 19. No abstract available.

PMID:
25527267
20.

Factorial clinical trials: a new approach to phase II neuro-oncology studies.

Iwamoto FM, Lassman AB.

Neuro Oncol. 2015 Feb;17(2):174-6. doi: 10.1093/neuonc/nou314. Epub 2014 Dec 1. No abstract available.

21.

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.

Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2014 Nov;16(11):1541-6. doi: 10.1093/neuonc/nou083. Epub 2014 Jul 4.

22.

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.

Iwamoto FM, Hormigo A.

Front Oncol. 2014 Apr 28;4:90. doi: 10.3389/fonc.2014.00090. eCollection 2014. Review.

23.

Semiautomated volumetric measurement on postcontrast MR imaging for analysis of recurrent and residual disease in glioblastoma multiforme.

Chow DS, Qi J, Guo X, Miloushev VZ, Iwamoto FM, Bruce JN, Lassman AB, Schwartz LH, Lignelli A, Zhao B, Filippi CG.

AJNR Am J Neuroradiol. 2014 Mar;35(3):498-503. doi: 10.3174/ajnr.A3724. Epub 2013 Aug 29.

24.

Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels.

Bozdag S, Li A, Riddick G, Kotliarov Y, Baysan M, Iwamoto FM, Cam MC, Kotliarova S, Fine HA.

PLoS One. 2013 Apr 29;8(4):e62982. doi: 10.1371/journal.pone.0062982. Print 2013.

25.

A phase I/II trial of vandetanib for patients with recurrent malignant glioma.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA.

Neuro Oncol. 2012 Dec;14(12):1519-26. doi: 10.1093/neuonc/nos265. Epub 2012 Oct 25.

26.

Continuous daily sunitinib for recurrent glioblastoma.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA.

J Neurooncol. 2013 Jan;111(1):41-8. doi: 10.1007/s11060-012-0988-z. Epub 2012 Oct 20.

PMID:
23086433
27.

Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.

Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE, Gutin PH.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):636-42. doi: 10.1016/j.ijrobp.2012.05.031. Epub 2012 Jul 3.

PMID:
22765876
28.

Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.

Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH, Iwamoto FM.

J Neurooncol. 2012 Sep;109(2):391-7. doi: 10.1007/s11060-012-0906-4. Epub 2012 Jun 12.

29.

Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB.

Neuro Oncol. 2012 Jun;14(6):761-7. doi: 10.1093/neuonc/nos065. Epub 2012 May 31.

30.

Atypical and anaplastic meningiomas treated with bevacizumab.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ.

J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29.

PMID:
22544653
31.

Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older.

Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, Suh JH, Vogelbaum MA, Peereboom DM, Zouaoui S, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Taillandier L, Abrey LE, DeAngelis LM, Shih JH, Iwamoto FM.

Cancer. 2012 Nov 15;118(22):5595-600. doi: 10.1002/cncr.27570. Epub 2012 Apr 19.

32.

Immediate titanium mesh cranioplasty for treatment of postcraniotomy infections.

Wind JJ, Ohaegbulam C, Iwamoto FM, Black PM, Park JK.

World Neurosurg. 2013 Jan;79(1):207.e11-3. doi: 10.1016/j.wneu.2011.02.013. Epub 2011 Nov 7.

33.

Spinal cord glioneuronal tumor with neuropil-like islands with 1p/19q deletion in an adult with low-grade cerebral oligodendroglioma.

Fraum TJ, Barak S, Pack S, Lonser RR, Fine HA, Quezado M, Iwamoto FM.

J Neurooncol. 2012 Apr;107(2):421-6. doi: 10.1007/s11060-011-0760-9. Epub 2011 Nov 15.

PMID:
22083647
34.

A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA.

Neuro Oncol. 2011 Oct;13(10):1143-50. doi: 10.1093/neuonc/nor091. Epub 2011 Aug 24.

35.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.

Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10.

36.

Magnetic resonance spectroscopy imaging in radiotherapy planning for recurrent glioma.

Ballangrud AM, Lymberis S, Thakur SB, Karimi S, Huang W, Abrey LE, Beal K, Iwamoto FM, Brennan C, Gutin PH, Chang J.

Med Phys. 2011 May;38(5):2724-30.

PMID:
21776809
37.

Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Deangelis LM, Holland EC, Hormigo A.

J Neurooncol. 2011 Dec;105(3):607-12. doi: 10.1007/s11060-011-0628-z. Epub 2011 Jun 28.

PMID:
21710351
38.

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS.

Neuro Oncol. 2011 Jun;13(6):649-59. doi: 10.1093/neuonc/nor040.

39.

Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy.

Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM.

J Neurooncol. 2011 Nov;105(2):281-9. doi: 10.1007/s11060-011-0579-4. Epub 2011 Apr 27.

40.

YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.

Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A.

Ann Neurol. 2011 Jul;70(1):163-9. doi: 10.1002/ana.22360. Epub 2011 Mar 9.

PMID:
21391238
41.

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.

Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA.

Neuro Oncol. 2011 May;13(5):509-16. doi: 10.1093/neuonc/nor017. Epub 2011 Mar 3.

42.

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome.

Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA.

Neurology. 2011 Jan 18;76(3):236-41. doi: 10.1212/WNL.0b013e3182074a69.

43.

Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM.

J Clin Oncol. 2010 Aug 20;28(24):3838-43. doi: 10.1200/JCO.2010.30.0582. Epub 2010 Jul 19.

44.

Primary brain tumors in the elderly.

Nayak L, Iwamoto FM.

Curr Neurol Neurosci Rep. 2010 Jul;10(4):252-8. doi: 10.1007/s11910-010-0110-x. Review.

PMID:
20461477
45.

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Chamberlain MC, Lassman AB, Iwamoto FM.

Neurology. 2010 Apr 13;74(15):1239-41. doi: 10.1212/WNL.0b013e3181d8a293. No abstract available.

PMID:
20385899
46.

Bevacizumab for malignant gliomas.

Iwamoto FM, Fine HA.

Arch Neurol. 2010 Mar;67(3):285-8. doi: 10.1001/archneurol.2010.11. Review.

PMID:
20212225
47.

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA.

Neuro Oncol. 2010 Aug;12(8):855-61. doi: 10.1093/neuonc/noq025. Epub 2010 Mar 3.

48.

Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.

Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA.

Cancer. 2010 Apr 1;116(7):1776-82. doi: 10.1002/cncr.24957.

49.

Clinical monograph: Clinical considerations for older patients with glioblastoma.

Abrey LE, Iwamoto FM, Finnegan T.

Clin Adv Hematol Oncol. 2010 Jan;8(1 Suppl 1):1-14; quiz 15-6. No abstract available.

PMID:
20237435
50.

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma.

Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB.

Neurology. 2009 Oct 13;73(15):1200-6. doi: 10.1212/WNL.0b013e3181bc0184.

Supplemental Content

Loading ...
Support Center